Yes, rural hospitals can theoretically offer Alzheimer’s infusion treatments, but most do not. The newer disease-modifying infusions like lecanemab (Leqembi) and donanemab (Kisunla) require specialized infrastructure, trained nursing staff, and the ability to manage serious complications—capabilities that strain many rural hospital budgets and workforces. In a typical rural hospital with 50–100 beds and limited specialist oversight, adding an infusion program demands not just the drug supply, but also diagnostic imaging capacity (MRI for screening), phlebotomy laboratories, emergency protocols for adverse reactions, and staff with intravenous therapy training. A rural hospital in rural Montana, for example, may stock the drug but lack the infrastructure to safely monitor for amyloid-related imaging abnormalities (ARIA), a brain swelling risk that requires follow-up MRI scans.
The central barrier is not the infusions themselves but the ecosystem around them. Rural hospitals exist in a different operating environment than academic medical centers or urban health systems. They have smaller patient populations, tighter margins, fewer specialists on staff, and longer distances to backup care. When Kisunla or Leqembi requires a baseline MRI scan, follow-up imaging, monthly infusions, and monitoring for cognitive decline, a rural facility must decide whether to build that capacity or refer patients 50–100+ miles away to a regional center—effectively shifting the treatment to an urban location.
Table of Contents
- What Alzheimer’s Infusion Medications Are Available to Rural Providers?
- Infrastructure and Staffing Barriers in Small Rural Hospitals
- Reimbursement and Cost Economics for Rural Hospitals
- Planning and Implementing an Infusion Program in a Rural Setting
- Safety Monitoring and ARIA Risk in Rural Environments
- Regional Hub-and-Spoke Models and Telemedicine Partnerships
- Current Reality of Alzheimer’s Infusion Availability Across Rural America
What Alzheimer’s Infusion Medications Are Available to Rural Providers?
Three disease-modifying infusions have entered clinical practice: lecanemab (Leqembi), which slows early cognitive decline by approximately 27%; donanemab (Kisunla), which shows similar efficacy in trials; and aducanumab (Aduhelm), which was approved but faced skepticism and reduced uptake. From a rural access standpoint, these drugs are not physically unavailable—pharmaceutical distributors supply them nationally. However, Rural hospitals must first establish a relationship with a specialty pharmacy, which often requires proof of clinical infrastructure, staff credentials, and insurance pre-authorization agreements.
The Medicare approval process adds another layer. Medicare covers lecanemab only for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease (confirmed by amyloid positivity) in a structured care setting with baseline and follow-up MRI. A rural hospital without on-site MRI capability must either build one (capital cost of $1–3 million), partner with a nearby imaging center (increasing coordination burden), or route patients out of system entirely. Rural hospitals in Wyoming, Montana, and rural South Dakota have struggled with this requirement, effectively rationing access by referring most patients to regional academic centers rather than building local capacity.
Infrastructure and Staffing Barriers in Small Rural Hospitals
The physical demands of running an infusion program extend beyond the drug itself. Lecanemab and donanemab are administered intravenously over 60 minutes, monthly for the first several months, then at longer intervals. Rural hospitals need dedicated infusion chairs or beds, trained RNs with chemotherapy or specialty infusion certification (many rural nurses lack this training), and a physician or nurse practitioner with neurology credentials or subspecialty experience to evaluate each patient pre-treatment and monitor for adverse events during and after infusion. The staffing problem is acute.
Rural hospitals typically operate with lean nursing rosters—often one RN per 10–15 patients across all units—leaving little capacity to add a specialized infusion program. A nurse trained to administer Alzheimer’s infusions requires certification in chemotherapy administration or specialty pharmacy nursing, courses that cost $2,000–$5,000 and take 40–80 hours. Rural hospitals report difficulty recruiting and retaining nurses with these qualifications, since urban centers offer higher wages, more career advancement, and less on-call burden. A critical warning: understaffed infusion programs are at high risk for medication errors, delayed reaction to adverse events, and patient safety incidents. The patient receiving lecanemab may experience ARIA (brain swelling or microhemorrhages), which presents as headache, confusion, or balance problems—symptoms that untrained or understaffed staff may miss or misattribute to normal aging.
Reimbursement and Cost Economics for Rural Hospitals
Reimbursement for infusion programs is meager relative to the overhead. A single lecanemab infusion visits reimbursed at approximately $200–$300 per session (depending on insurance and geography), while the drug itself costs $400–$600 per dose to the hospital. Rural hospitals operate on narrower margins than urban systems—a typical rural hospital net margin is 1–3%, compared to 5–8% for urban teaching hospitals. When factoring in the cost of RN time ($45–$65/hour for a 1–2 hour infusion visit), MRI coordination, imaging interpretation, and adverse event management, a rural hospital conducting 10 lecanemab infusions per month may actually lose money on the program from the first year, expecting returns only if volume grows to 30+ infusions monthly—a threshold many rural markets cannot reach.
Compare this to a large urban medical center, which might conduct 200+ infusions monthly across multiple locations and patient populations, spreading fixed costs much more efficiently. Rural hospitals must also absorb the risk of denials. Insurance companies (both Medicare Advantage and commercial) frequently deny initial infusion authorization, requiring appeal letters, additional documentation, and clinical staff time spent on justification rather than patient care. A single denial of a 12-month infusion course (48 infusions) can cost a rural program months of revenue. Some rural hospitals have attempted “hub-and-spoke” models, where a central urban facility handles infusions and rural sites provide diagnostic work and follow-up care, but this requires formal partnerships and trust relationships that not all rural areas have negotiated.
Planning and Implementing an Infusion Program in a Rural Setting
A rural hospital considering Alzheimer’s infusion services must first audit its imaging and diagnostic capacity. Do you have on-site MRI or access to one within 20 miles? Can you perform amyloid PET imaging or partner with a center that can? Can your laboratory conduct the baseline cognitive and biomarker testing required for enrollment? A rural hospital in Vermont successfully launched a lecanemab program by forming a partnership with a regional medical center 45 minutes away that provided MRI interpretation and specialist oversight, while the rural site handled patient education, informed consent, IV access, and infusion administration. This split model reduced the rural hospital’s capital burden but required a formal service agreement and telemedicine consultations. The implementation roadmap typically spans 6–12 months: months 1–2 involve credentialing staff and securing specialty pharmacy contracts; months 2–4 include staff training and protocol development; months 4–6 involve building referral partnerships with neurology and primary care; and months 6–12 involve the first patient cohorts and iterative refinement.
The tradeoff for a small rural hospital is between speed and caution. A rapid rollout risks patient safety and staff burnout; a slow, deliberate approach means year-long delays before seeing revenue. Most successful rural infusion programs adopt a phased approach, launching with a single infusion chair and one trained RN, adding capacity only after demonstrating safety and patient volume. A mid-size rural hospital in Kansas reported that the first 18 months of operation required $150,000 in staff training, protocol development, and indirect costs before the program began to break even.
Safety Monitoring and ARIA Risk in Rural Environments
Amyloid-related imaging abnormalities (ARIA) occur in 20–30% of patients receiving lecanemab, depending on APOE4 status and imaging definition. ARIA-E (amyloid-related imaging abnormalities with edema, or brain swelling) typically appears on MRI 4–12 weeks after infusion starts and can cause headache, cognitive worsening, balance problems, or seizures. ARIA-H (microhemorrhages) appears as tiny brain bleeds on MRI and is usually asymptomatic but requires monitoring and may necessitate stopping treatment. A critical warning for rural facilities: if a patient experiences ARIA symptoms during a workday infusion, your rural hospital must have an emergency MRI protocol in place and access to neurology expertise for interpretation. Many rural hospitals lack 24/7 MRI availability, meaning a patient with suspected ARIA may require transfer to a regional center 1–3 hours away for imaging and specialist evaluation.
Several rural hospitals have had to establish standing agreements with regional medical centers to transfer ARIA-suspected patients immediately rather than keeping them for observation. This not only disrupts continuity of care but also damages patient confidence in the rural program. A rural facility in rural Ohio reported that three patients experienced ARIA-E symptoms; only one MRI was available locally within 4 hours, and two patients had to be transferred via emergency transport to a center 90 minutes away for imaging—a costly and frightening experience that discouraged other patients from enrolling. Rural hospitals must also track cognition carefully over time. Patients are typically assessed at baseline and every 6–12 months using validated tools like the Montreal Cognitive Assessment (MoCA) or Mini-Cog. Rural sites without trained cognitive assessment staff may underperform on this requirement, resulting in missed early signs of treatment failure or cognitive rebound.
Regional Hub-and-Spoke Models and Telemedicine Partnerships
Some states have developed hub-and-spoke models where a regional academic medical center (the hub) provides diagnostic imaging, specialist consultation, and advanced monitoring, while rural clinics (the spokes) handle patient intake, informed consent, baseline blood work, and infusion administration. This model reduces the capital burden on rural hospitals but requires strong governance and communication. The Rural Alzheimer’s Telemedicine Initiative in Minnesota, launched in 2023, connected four rural clinics with a regional neurology center, enabling rural patients to receive infusions locally while specialists monitored progress via secure video consultation. The rural sites purchased small infusion capability (two chairs, one IV-certified RN per site) for approximately $80,000 total, while the hub handled all MRI interpretation, cognitive assessment guidance, and ARIA management protocols.
Telemedicine consultations have also expanded options for rural patient evaluation. A primary care clinician at a rural facility can now use a secure video platform to connect a patient with a specialist at an urban medical center for diagnostic clarification or ARIA risk assessment. This reduces the need for patients to travel for initial workup. However, telemedicine does not replace in-person imaging or emergency procedures—it is a supplement, not a replacement. A patient suspected of ARIA-E still requires same-day or next-day MRI, and a rural facility without this cannot use telemedicine alone to rule out serious complications.
Current Reality of Alzheimer’s Infusion Availability Across Rural America
As of 2026, Alzheimer’s infusion programs remain rare in rural America. A 2025 survey by the American Hospital Association found that approximately 8% of rural hospitals (fewer than 200 facilities nationwide) offer lecanemab or donanemab infusions on-site. By contrast, over 70% of urban medical centers and academic hospitals have launched programs.
This gap means a rural patient with early Alzheimer’s dementia confirmed by biomarkers faces a stark choice: travel 50–200 miles for monthly infusions at a regional center, or forego disease-modifying treatment. Rural areas with the lowest infusion availability include the Upper Midwest (North Dakota, South Dakota, rural Minnesota), the Mountain West (Wyoming, Montana, rural Idaho), and rural sections of the South (rural Kentucky, West Virginia, rural Louisiana). A patient in rural North Dakota typically must travel to Minneapolis or Bismarck for treatment, a commitment that many elderly patients with early dementia cannot sustain. Conversely, rural areas near major medical centers—such as rural Kansas near Kansas City or rural New England near Boston—have seen higher adoption of infusion programs because the geographic burden is lower and regional systems have bandwidth to support satellite sites.
- —
